Immuron (IMRN) Notes Payables (2017 - 2019)
Immuron (IMRN) posted quarterly Notes Payables of $98120.0 for Q4 2019, down 0.66% on a QoQ basis from $98775.4 in Q2 2017.
Immuron (IMRN) Notes Payables (2017 - 2019) Analysis & Trends
Immuron (IMRN) has reported Notes Payables for 2 consecutive years, with $98120.0 the latest figure, recorded in Q4 2019.
- Quarterly Notes Payables changed N/A year-over-year to $98120.0 in Q4 2019, while the trailing twelve-month figure through Dec 2019 was $98120.0 (changed N/A YoY) and the FY2019 annual result came in at $98120.0, changed N/A from the prior year.
- Notes Payables eased to $98120.0 in Q4 2019 per IMRN's latest filing, from $98775.4 in the prior quarter.
- Over the last five years, Notes Payables for IMRN reached as high as $98775.4 in Q2 2017 and fell as low as $98120.0 in Q4 2019.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - |
| 10 | Immuron | 270.20 Mn | 258.54 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2019 | 98,120.00 |
| Jun 30, 2017 | 98,775.41 |